Human T Cell expansion has become an increasingly important tool in the development of both autologous and allogeneic immunotherapies, as T cells emerge as an exciting option to treat a wide range of diseases. Major components used to expand these cells include human and bovine serum, as well as proteins derived from these substances. These components not only have the potential to introduce harmful pathogens to the already compromised patient in a clinical setting, but they also have significant limitations in the ability to ensure robust and reproducible performance in cell culture systems. Even so-called “xeno-free” media—often confused with chemically defined, animal-component-free media—contain proteins derived from human or bovine serum. OptiPEAK T Lymphocyte media (product No. 777OPT069) supports the growth and expansion of human primary T cells and contains only synthetic and recombinant components. This medium is considered blood-free and all components are chemically defined, providing robust performance without compromising growth, safety, or phenotype.
This application note demonstrates how OptiPeak T Lymphocyte blood-free medium’s potential as a viable and regulatory-friendly option for T cell immunotherapy manufacturing.